Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

December 31, 2011

Conditions
LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Clofarabine with Busulfan

Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days

Trial Locations (1)

75246

Baylor University Medical Center, Dallas

Sponsors
All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Baylor Research Institute

OTHER